Skip to main content

Table 3 Details of NGS analysis in 6 samples at lower RNA input level

From: Clinicopathological investigation of secretory carcinoma cases including a successful treatment outcome using entrectinib for high-grade transformation: a case report

Case#

Specimen site

Sample collection date

RNA input (ng)

Gene fusion

No. valid fusion reads

% of reads supporting fusion

No. unique start sites

Breakpoints

1

Parotid

2015

10

ETV6-NTRK3

8

13.56

3

chr12:12022903 chr15:88483984

    

NTRK3-ETV6†

6

10.17

3

chr15:88576088 chr12:12037379

2

Lymph node

2016

10

ETV6-NTRK3

212

70.20

96

chr12:12022903 chr15:88483984

    

NTRK3-ETV6†

76

48.41

44

chr15:88576088 chr12:12037379

3–1*

Parotid

1994

10

ETV6-NTRK3

23

34.33

10

chr12:12022903 chr15:88483984

3–2*

Parotid

2008

10

ETV6-NTRK3

8

15.38

4

chr12:12022903 chr15:88483984

3–3*

Parotid

2012

10

ETV6-NTRK3

779

55.25

162

chr12:12022903 chr15:88483984

3–4*

Lymph node

2012

10

ETV6-NTRK3

255

72.24

97

chr12:12022903 chr15:88483984

  1. *3–1, the initial tumor; 3–2, 3rd recurrence; 3–3, 5th recurrence; 3–4, and 6th recurrence of case 3, respectively
  2. †Reciprocal fusion which is secondary and non –driver mutation